Special Issue

Research of Bacteriophages Antimicrobial Activity

Message from the Guest Editor

The bacteriophages are our allies in the fight against drug-resistant bacteria that deserve our undivided attention. In particular, the ability of phages to infect and destroy bacterial cells poses a possibility to replace traditional antimicrobial therapies or to use them together within phage antibiotic combined therapy. A great deal of phage research also reveals the unique evolutionary trajectories and their important role in shaping the environmental microbiome. This Special Issue seeks manuscript submissions that further our understanding of the antimicrobial activity of the bacteriophages. Submissions on the bacteriophage biology, role of phages in shaping the human/animal microbiome, phage genetic engineering, bacterial host resistance, the influence of external factor on phage activity, and phage-antibiotic synergy are especially encouraged. **Keywords**: bacteriophages; phage therapy; phage ecology, phage biocontrol; phage antibiotic synergy; antimicrobial resistance; phages protein; endolysisns

Guest Editor

Dr. Barbara Dolegowska
Department of Microbiology, Immunology and Laboratory Medicine, Pomeranian Medical University in Szczecin, Szczecin, Poland

Deadline for manuscript submissions

closed (30 June 2021)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/56199

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI